Evaluating IL-21 as a Potential Therapeutic Target in Crohn’s Disease

Table 1

Human tissues used in the present study.

Tissue	Processed			Vendor
	FF (ISH)	FFPE (IHC)	PFPE (IHC)
Positive control tissue
Tonsil	3		5	Rigshospitalet (Copenhagen, DK)
Normal non-IBD controls
Colon	14	15		Cambridge BioScience (Cambridge, UK)
Small intestine	3	3		Cambridge BioScience (Cambridge, UK)
Crohn’s disease
Colon	8	10		Cambridge BioScience (Cambridge, UK)
Small intestine	7	10		Cambridge BioScience (Cambridge, UK)

FF: fresh frozen OCT embedded; FFPE: formalin-fixed paraffin embedded; IHC: immunohistochemistry; IBD: inflammatory bowel disease; ISH: in situ hybridization; PFPE: paraformaldehyde-fixed paraffin embedded. Number of samples is listed. Pathologically classified as being within normal limits obtained from patients with adenocarcinoma, gastrointestinal tumour of small intestine, lipoma, dysplasia of bile duct epithelium, and familial adenomatous polyposis.